Is Fulcrum Therapeutics Stock a Good Investment?
Fulcrum Therapeutics Investment Advice | FULC |
- Examine Fulcrum Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Fulcrum Therapeutics' leadership team and their track record. Good management can help Fulcrum Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Fulcrum Therapeutics' business and its evolving consumer preferences.
- Compare Fulcrum Therapeutics' performance and market position to its competitors. Analyze how Fulcrum Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Fulcrum Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Fulcrum Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Fulcrum Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Fulcrum Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Fulcrum Therapeutics Stock
Researching Fulcrum Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulcrum Therapeutics recorded a loss per share of 0.29. The entity had not issued any dividends in recent years.
To determine if Fulcrum Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fulcrum Therapeutics' research are outlined below:
| Fulcrum Therapeutics generated a negative expected return over the last 90 days | |
| Fulcrum Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.81 M. Net Loss for the year was (97.33 M) with loss before overhead, payroll, taxes, and interest of (70.44 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (90.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fulcrum Therapeutics stock hits 52-week low at 2.87 - Investing.com |
Fulcrum Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fulcrum Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fulcrum Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Fulcrum Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Fulcrum Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2024-11-05 | 2024-09-30 | -0.41 | -0.4633 | -0.0533 | 13 | ||
2023-08-03 | 2023-06-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2021-11-04 | 2021-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2021-03-04 | 2020-12-31 | -0.72 | -0.64 | 0.08 | 11 | ||
2022-11-08 | 2022-09-30 | -0.61 | -0.51 | 0.1 | 16 | ||
2021-05-06 | 2021-03-31 | -0.66 | -0.54 | 0.12 | 18 | ||
2020-08-11 | 2020-06-30 | -0.78 | -0.66 | 0.12 | 15 |
Fulcrum Therapeutics Target Price Consensus
Fulcrum target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Fulcrum Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Buy |
Most Fulcrum analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Fulcrum stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Fulcrum Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationFulcrum Therapeutics Target Price Projection
Fulcrum Therapeutics' current and average target prices are 3.88 and 10.21, respectively. The current price of Fulcrum Therapeutics is the price at which Fulcrum Therapeutics is currently trading. On the other hand, Fulcrum Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Fulcrum Therapeutics Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On Fulcrum Therapeutics Target Price
Fulcrum Therapeutics Analyst Ratings
Fulcrum Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Fulcrum Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Fulcrum Therapeutics' financials, market performance, and future outlook by experienced professionals. Fulcrum Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Fulcrum Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fulcrum Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulcrum Therapeutics backward and forwards among themselves. Fulcrum Therapeutics' institutional investor refers to the entity that pools money to purchase Fulcrum Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Suvretta Capital Management, Llc | 2024-09-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.1 M | Goldman Sachs Group Inc | 2024-09-30 | 928 K | Deutsche Bank Ag | 2024-06-30 | 849.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 757.7 K | Woodline Partners Lp | 2024-09-30 | 670.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 569.2 K | Northern Trust Corp | 2024-09-30 | 567.7 K | Ra Capital Management, Llc | 2024-09-30 | 10.2 M | Tcg Crossover Management, Llc | 2024-09-30 | 5.2 M |
Fulcrum Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 213.06 M.Market Cap |
|
Fulcrum Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.41) | (0.43) |
Determining Fulcrum Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Fulcrum Therapeutics is a good buy. For example, gross profit margin measures Fulcrum Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fulcrum Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Fulcrum Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fulcrum Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fulcrum Therapeutics' management manipulating its earnings.
Evaluate Fulcrum Therapeutics' management efficiency
Fulcrum Therapeutics has return on total asset (ROA) of (0.0689) % which means that it has lost $0.0689 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0737) %, meaning that it created substantial loss on money invested by shareholders. Fulcrum Therapeutics' management efficiency ratios could be used to measure how well Fulcrum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.48. At present, Fulcrum Therapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 164.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.84 | 3.49 | |
| Tangible Book Value Per Share | 3.84 | 3.49 | |
| Enterprise Value Over EBITDA | (3.68) | (3.86) | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | (3.68) | (3.86) | |
| Price Fair Value | 1.76 | 1.67 |
The decision-making processes within Fulcrum Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 2.235 |
Basic technical analysis of Fulcrum Stock
As of the 2nd of December, Fulcrum Therapeutics shows the Standard Deviation of 8.83, variance of 77.91, and Mean Deviation of 4.22. Fulcrum Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fulcrum Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulcrum Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulcrum Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulcrum Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fulcrum Therapeutics' Outstanding Corporate Bonds
Fulcrum Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fulcrum Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fulcrum bonds can be classified according to their maturity, which is the date when Fulcrum Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US359678AC31 Corp BondUS359678AC31 | View | |
| HB Fuller 4 Corp BondUS359694AB24 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Fulcrum Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Fulcrum Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.78) | |||
| Mean Deviation | 4.22 | |||
| Coefficient Of Variation | (1,340) | |||
| Standard Deviation | 8.83 | |||
| Variance | 77.91 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.14) | |||
| Treynor Ratio | (0.79) | |||
| Maximum Drawdown | 66.11 | |||
| Value At Risk | (6.74) | |||
| Potential Upside | 9.43 | |||
| Skewness | (4.91) | |||
| Kurtosis | 34.41 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.78) | |||
| Mean Deviation | 4.22 | |||
| Coefficient Of Variation | (1,340) | |||
| Standard Deviation | 8.83 | |||
| Variance | 77.91 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.14) | |||
| Treynor Ratio | (0.79) | |||
| Maximum Drawdown | 66.11 | |||
| Value At Risk | (6.74) | |||
| Potential Upside | 9.43 | |||
| Skewness | (4.91) | |||
| Kurtosis | 34.41 |
Consider Fulcrum Therapeutics' intraday indicators
Fulcrum Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fulcrum Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 25161.61 | |||
| Daily Balance Of Power | 0.15 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 3.88 | |||
| Day Typical Price | 3.88 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.03 |
Fulcrum Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F3 | 23rd of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Fulcrum Stock media impact
Far too much social signal, news, headlines, and media speculation about Fulcrum Therapeutics that are available to investors today. That information is available publicly through Fulcrum media outlets and privately through word of mouth or via Fulcrum internal channels. However, regardless of the origin, that massive amount of Fulcrum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fulcrum Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fulcrum Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fulcrum Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fulcrum Therapeutics alpha.
Fulcrum Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Fulcrum Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fulcrum Therapeutics Corporate Management
| Rudolf MD | Founder | Profile | |
| CPA CMA | Chief Officer | Profile | |
| Jeffrey Jacobs | Chief Officer | Profile | |
| Mel Hayes | Executive Experience | Profile | |
| Paul Bruno | Senior Development | Profile | |
| Bryan Stuart | CEO Pres | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 1.317 | Quarterly Revenue Growth 89.909 | Return On Assets (0.07) | Return On Equity (0.07) |
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Fulcrum Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.